Previous 10 | Next 10 |
Endonovo Therapeutics (OTCQB: ENDV) today announced the evaluation of its SofPulse(R) device at major universities for orthopedic surgeries. Endonovo’s FDA-Cleared SofPulse(R) is a non-invasive device utilized for the reduction of postoperative pain and edema and represents a low-cost...
Los Angeles, CA, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced their SofPulse ® device is being evaluated at major universities for orthopedic surgeries. SofPulse ® is Endonovo’s FDA-Cleared, no...
Endonovo Therapeutics (OTCQB: ENDV) today announced the reduction of current liabilities and restructuring of the balance sheet through the approved modification of the terms of the Preferred C shares. “Strengthening our balance sheet is a priority we feel is instrumental in our conti...
Los Angeles, CA, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") is pleased to announce the reduction of current liabilities and restructuring of the balance sheet through the approved modification of the terms of the Preferred ...
Endonovo Therapeutics (OTCQB: ENDV) today announced that it has secured sales of SofPulse(R), the company’s FDA-Cleared, non-invasive device utilized for the reduction of postoperative pain and edema, to multiple plastic surgery centers. “SofPulse(R) main distribution model is ...
Los Angeles, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced sales of SofPulse ® units to multiple Plastic Surgery Centers. SofPulse ® is Endonovo’s FDA-Cleared, non-invasive device utilized f...
Endonovo Therapeutics (OTCQB: ENDV) today announced initial sales of SofPulse(R) units into a VA hospital in Texas. Endonovo’s FDA-Cleared non-invasive device for reduction of postoperative pain and edema, SofPulse(R) represents a low-cost, drug-free solution to reduce use of opioids ...
Los Angeles, CA, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced initial sales of SofPulse ® units into a VA hospital in Texas. SofPulse ® is Endonovo’s FDA-Cleared non-invasive device for reduct...
● This furthers Endonovo’s strategy to commercialize and protect its Electroceutical(s) ® Los Angeles, CA, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced that the United States Patent and Tr...
Issuance of U.S. Patent No. 15217855 Further Bolsters Endonovo’s Intellectual Patent Portfolio Los Angeles, CA, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDVD / ENDV) ("Endonovo" or the "Company"), today announced that the United States Patent and Tr...
News, Short Squeeze, Breakout and More Instantly...
Endonovo Therapeutics Inc Company Name:
ENDV Stock Symbol:
OTCMKTS Market:
Endonovo Therapeutics Inc Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...